CCL

Összesen 19 találat.
#/oldal:
Részletezés:
Rendezés:

1.

001-es BibID:BIBFORM103405
035-os BibID:(cikkazonosító)2060 (WoS)000858038100001 (Scopus)85138606448
Első szerző:Beke-Varga Alexandra Edit (molekuláris biológus)
Cím:Suppressing the PI3K/AKT Pathway by miR-30d-5p Mimic Sensitizes Ovarian Cancer Cells to Cell Death Induced by High-Dose Estrogen / Varga Alexandra, Márton Éva, Markovics Arnold, Penyige András, Balogh István, Nagy Bálint, Szilágyi Melinda
Dátum:2022
ISSN:2227-9059
Megjegyzések:MicroRNAs are short non-coding RNA molecules that are involved in tumor development and are considered to be promising candidates in cancer therapy. Here, we studied the role of miR-30s in the pathophysiology of ovarian cancer. According to our results miR-30a-5p, miR-30d-5p, and miR-30e-5p were overexpressed in the estrogen receptor alpha (ER alpha)-expressing PEO1 cell line compared to A2780 that lacks this receptor. Furthermore, the expression of miR-30a-5p, miR-30d-5p, and miR-30e-5p were induced in response to high-dose estrogen treatment in PEO1 where intensive cell death was observed according to the induction of apoptosis and autophagy. Lacking or blocking ER alpha function reduced tolerance to high-dose estrogen that suggests the importance of ER alpha-mediated estrogen response in the maintenance of proliferation. MiR-30d-5p mimic reduced cell proliferation in both A2780 and PEO1. Furthermore, it decreased the tolerance of PEO1 cells to high-dose estrogen by blocking the ER alpha-mediated estrogen response. This was accompanied by decreased SOX4 expression that is thought to be involved in the regulation of the PI3K/AKT pathway. Blocking this pathway by AZD8835 led to the same results. MiR-30d-5p or AZD8835 sensitized PEO1 cells to tamoxifen. We suggest that miR-30d-5p might be a promising candidate in the therapy of ovarian cancer.
Tárgyszavak:Orvostudományok Elméleti orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
miR-30
ovarian cancer
estrogen receptor
high-dose estrogen
cell proliferation
cell death
sox4
PI3K/AKT
cancer therapy
tamoxifen
Megjelenés:Biomedicines. - 10 : 9 (2022), p. 1-19. -
További szerzők:Márton Éva (1992-) (biológus) Markovics Arnold (1988-) (molekuláris biológus) Penyige András (1954-) (molekuláris genetikus) Balogh István (1972-) (molekuláris biológus, genetikus) Nagy Bálint (1956-) (molekuláris genetikus) Szilágyi Melinda (1984-) (biológus)
Pályázati támogatás:EFOP-3.6.3-VEKOP-16-2017-00009
EFOP
138021
OTKA
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

2.

001-es BibID:BIBFORM094352
035-os BibID:(cikkazonosító)5058 (scopus)85105433955 (wos)000662004700001
Első szerző:Géczi Dóra (biotechnológus)
Cím:Analysis of Circulating miRNA Profile in Plasma Samples of Glioblastoma Patients / Dóra Géczi, Bálint Nagy, Melinda Szilágyi, András Penyige, Álmos Klekner, Adrienn Jenei, József Virga, Zsuzsanna Birkó
Dátum:2021
ISSN:1661-6596 1422-0067
Megjegyzések:Background: Glioblastoma multiforme (GBM) is among the most aggressive cancers with a poor prognosis. Treatment options are limited, clinicians lack efficient prognostic and predictive markers. Circulating miRNAs?besides being important regulators of cancer development?may have potential as diagnostic biomarkers of GBM. (2) Methods: In this study, profiling of 798 human miRNAs was performed on blood plasma samples from 6 healthy individuals and 6 patients with GBM, using a NanoString nCounter Analysis System. To validate our results, five miRNAs (hsa-miR-433-3p, hsa-miR-362-3p, hsa-miR-195-5p, hsa-miR-133a-3p, and hsa-miR-29a-3p) were randomly chosen for RT-qPCR detection. (3) Results: In all, 53 miRNAs were significantly differentially expressed in plasma samples of GBM patients when data were filtered for FC 1 and FDR 0.1. Target genes of the top 39 differentially expressed miRNAs were identified, and we carried out functional annotation and pathway enrichment analysis of target genes via GO and KEGG-based tools. General and cortex-specific protein?protein interaction networks were constructed from the target genes of top miRNAs to assess their functional connections. (4) Conclusions: We demonstrated that plasma microRNA profiles are promising diagnostic and prognostic molecular biomarkers that may find an actual application in the clinical practice of GBM, although more studies are needed to validate our results.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
glioblastoma
circulating miRNA
blood plasma
network analysis
biomarker
NanoString
Megjelenés:International Journal Of Molecular Sciences. - 22 : 10 (2021), p. 1-20. -
További szerzők:Nagy Bálint (1956-) (molekuláris genetikus) Szilágyi Melinda (1984-) (biológus) Penyige András (1954-) (molekuláris genetikus) Klekner Álmos (1970-) (idegsebész) Jenei Adrienn (1978-) (biológus, kémikus) Virga József (1989-) Hádáné Birkó Zsuzsanna (1971-) (molekuláris genetikus)
Pályázati támogatás:2017-1.2.1-NKP-2017-00002
NKP
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

3.

001-es BibID:BIBFORM078520
035-os BibID:(PMID)31002856 (WoS)000466942100010 (Scopus)85064701689
Első szerző:Keserű Judit (molekuláris genetikus)
Cím:Detection of cell-free, exosomal and whole blood mitochondrial DNA copy number in plasma or whole blood of patients with serous epithelial ovarian cancer / Keserű J. S., Soltész B., Lukács J., Márton É., Szilágyi-Bónizs M., Penyige A., Póka R., Nagy B.
Dátum:2019
ISSN:0168-1656
Megjegyzések:Ovarian tumor is one of the leading causes of cancer among women. Patients are diagnosed at an advanced stage, usually. There is a need for new specific and sensitive biomarkers. Mitochondrial DNA copy number change was observed in various cancers. Our aim was to detect mitochondrial DNA copy number in whole blood (wb-mtDNA) and in plasma (cell-free and exosome encapsulated mtDNA) in patients with serous epithelial ovarian tumor. DNA was isolated from EDTA blood and plasma obtained from 24 patients and 24 healthy controls. Exosomes were isolated from cell-free plasma, and exosome encapsulated DNA (exoDNA) was extracted. Quantitative-real-time PCR was performed with Human Mitochondrial DNA (mtDNA) Monitoring Primer Set. Kruskall?Wallis and Mann?Whitney U test were used for data analysis. Wb-mtDNA copy number was significantly different among healthy controls and patients in multiple comparison (p?=?0.0090 considering FIGO stage independently, and p?=?0.0048 considering early- and late-stage cancers). There was a significant decrease among early-stage, all advanced stage and all cancer patients (FIGO I: 32.5?±?8.3, p?=?0.0061; FIGO III?+?IV: 37.2?±?13.7 p?=?0.0139; FIGO I?+?III?+?IV: 35.6?±?12.2, p?=?0.0017) or FIGO III patients alone (32.8?±?5.6, p?=?0.00089) compared to healthy controls. We found significant increase in copy number in exosomal mtDNA in cancer patients (236.0?±?499.0, p?=?0.0155), advanced-stage cancer patients (333.0?±?575.0, p?=?0.0095), of FIGO III (362.0?±?609.2, p?=?0.0494), and FIGO IV (304.0?±?585.0, p?=?0.0393) patients alone but not in samples of FIGO I patients (10.0?±?3.5, p?=?0.3907). In multiple comparison the increase was significant considering early- and late-stage cancers (p?=?0.0253). Cell-free mtDNA copy numbers were not increased significantly. We found the highest copy number of mtDNA in exosomes, followed by plasma and peripheral blood in late-stage cancer patients. We observed significant difference in wb-mtDNA copy number between healthy controls and both early- and late-stage cancer patients.
Tárgyszavak:Orvostudományok Elméleti orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Cell-free mtDNA
Exosomal mtDNA
Mitochondrial DNA
Serous ovarian cancer
Megjelenés:Journal of Biotechnology. - 298 (2019), p. 76-81. -
További szerzők:Soltész Beáta (1987-) (molekuláris biológus) Lukács János (1975-) (szülész-nőgyógyász, genetikus) Márton Éva (1992-) (biológus) Szilágyi Melinda (1984-) (biológus) Penyige András (1954-) (molekuláris genetikus) Póka Róbert (1960-) (szülész-nőgyógyász, klinikai onkológus) Nagy Bálint (1956-) (molekuláris genetikus)
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

4.

001-es BibID:BIBFORM073381
035-os BibID:(cikkazonosító)E-P18.36 (WoS)000489312608202
Első szerző:Keserű Judit (molekuláris genetikus)
Cím:Determination of miR-196a Single Nucleotide Polymorphism (SNP) with melting-curve analysis in the population of patients with ovarian cancer / J. S. Keserű, J. Lukács, B. Soltész, K. Szirák, Z. Birkó, A. Penyige, B. Nagy, R. Póka
Dátum:2018
ISSN:1018-4813 1476-5438
Megjegyzések:Introduction: miRNA molecules are short, non-coding sequences regulating gene expression after transcription. They are important in the development, progression and treatability of tumours. Single Nucleotide Polymorphism (SNP) is the most frequent type of genetic polymorphism. That is true also for miRNAs and their polymorphisms can cause alterations in the gene expression profile. miR-196a was also linked to the genesis of different tumours.Aim: Search for correlation between miR-196a polymorphism and development of ovarian cancer.Materials and Methods: 75 patients with ovarian cancer and 75 healthy persons were investigated. 15-16 mL blood anticoagulated with EDTA was drawn. DNA was isolated with silica absorption method and the melting curve of PCR products generated with LightSnip kit (TibMolbiol, Berlin, Germany) developed for miR-196a (rs11614913) SNP was determined by LightCycler 96 equipment. Allele and genotype frequencies were specified and Student t-test was applied for statistical analysis of data.Results: The Tm of PCR products were 55.5?C for T allele and 62.6?C for C allele with melting-curve analysis. T allele occurred in 32.66% in population of patients and in 40.66% in control group. Genotypes among control persons were 18.66% for TT, 44.0% for TC, and 37.33% CC, while in case of patients these frequencies were 12.0%, 41.33%, and 46.66%, respectively (p=0.3815).Conclusion: miR-196a influences the expression of 684 genes, it requires further complex investigation, whether it is involved in the development of ovarian cancer.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idézhető absztrakt
folyóiratcikk
ovarian cancer
miR-196a
SNP
Megjelenés:European Journal of Human Genetics. - 26 : Suppl. (2018), p. 1. -
További szerzők:Lukács János (1975-) (szülész-nőgyógyász, genetikus) Soltész Beáta (1987-) (molekuláris biológus) Szirák Krisztina (1973-) (molekuláris genetikus) Hádáné Birkó Zsuzsanna (1971-) (molekuláris genetikus) Penyige András (1954-) (molekuláris genetikus) Nagy Bálint (1956-) (molekuláris genetikus) Póka Róbert (1960-) (szülész-nőgyógyász, klinikai onkológus)
Internet cím:Szerző által megadott URL
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

5.

001-es BibID:BIBFORM078797
035-os BibID:(PMID)30904593 (WoS)000464978100008 (Scopus)85063796275
Első szerző:Lukács János (szülész-nőgyógyász, genetikus)
Cím:Identification of miR-146a and miR-196a-2 single nucleotide polymorphisms at patients with high-grade serous ovarian cancer / János Lukács, Beáta Soltész, András Penyige, Bálint Nagy, Róbert Póka
Dátum:2019
ISSN:0168-1656
Megjegyzések:MicroRNAs play an essential role in the regulation of gene expression and tumor development. Single nucleotide polymorphism (SNP) can be observed in miRNAs and could influence gene expression. We aimed to identify miR-146a rs2910164 and miR-196a-2 rs11614913 polymorphisms in ovarian cancer patients and controls. 75 patients and 75 controls were involved. DNA was isolated from blood samples. MiR-146a rs2910164 and miR-196a-2 rs11614913 were determined by LightSnip kit. We used melting curve analysis for allele classification. Network analysis was made to find common target genes. We detected 72.67% G allele frequency of miR-146a rs2910164 in controls and 82.00% in patients group (p?=?0,053). GG, GC and CC genotypes occurred with 53.33%, 38.67% and 8.00% among controls, with 65.33%, 33.33% and 1.33% among patients, (p?=?0.0917). Allele C of miR-196a-2 rs11614913 occurred in 59.33% of controls and in 67.33% of patients (p?=?0.15). CC, CT and TT genotypes occurred with 37.33%, 44.00%, and 18.67% frequency in controls, with 46.67%; 41.33% and 12.00% in patients (p?=?0.3815). Network analysis found ATG9A, LBR, MBD4 and RUFY2 genes to be targets for both miRNAs. SNPs of miR-146a and miR-196a-2 showed no significant differences between patients and controls. More investigations are required to clarify the exact role of these SNPs in ovarian cancer.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Ovarian cancer
SNP
miR-146a
miR-196a-2
miRNA
Megjelenés:Journal Of Biotechnology. - 297 (2019), p. 54-57. -
További szerzők:Soltész Beáta (1987-) (molekuláris biológus) Penyige András (1954-) (molekuláris genetikus) Nagy Bálint (1956-) (molekuláris genetikus) Póka Róbert (1960-) (szülész-nőgyógyász, klinikai onkológus)
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

6.

001-es BibID:BIBFORM070822
Első szerző:Lukács János (szülész-nőgyógyász, genetikus)
Cím:A miR-146a és miR-196a-2 egynukleotidos polimorfizmusának meghatározása alacsonyan differenciált szerózus papilláris ováriumtumoros betegek mintáiban / Lukács János, Soltész Beáta, Penyige András, Nagy Bálint, Póka Róbert
Dátum:2017
Tárgyszavak:Orvostudományok Klinikai orvostudományok magyar nyelvű folyóiratközlemény hazai lapban
miRNS
Petefészekrák
Megjelenés:Magyar Nőorvosok Lapja 80 (2017), p. 226-230. -
További szerzők:Soltész Beáta Penyige András (1954-) (molekuláris genetikus) Nagy Bálint (1956-) (molekuláris genetikus) Póka Róbert (1960-) (szülész-nőgyógyász, klinikai onkológus)
Internet cím:Intézményi repozitóriumban (DEA) tárolt változat
Borító:

7.

001-es BibID:BIBFORM108635
035-os BibID:(cikkazonosító)140 (Scopus)85148964475
Első szerző:Márton Éva (biológus)
Cím:Comparative Analysis of Transcriptomic Changes including mRNA and microRNA Expression Induced by the Xenoestrogens Zearalenone and Bisphenol A in Human Ovarian Cells / Éva Márton, Alexandra Varga, András Penyige, Zsuzsanna Birkó, István Balogh, Bálint Nagy, Melinda Szilágyi
Dátum:2023
ISSN:2072-6651
Megjegyzések:Xenoestrogens are natural or synthetic compounds that mimic the effect of endogenous estrogens and might cause cancer. We aimed to compare the global transcriptomic response to zearalenone (ZEA; mycotoxin) and bisphenol A (BPA; plastic additive) with the effect of physiological estradiol (E2) in the PEO1 human ovarian cell line by mRNA and microRNA sequencing. Estrogen exposure induced remarkable transcriptomic changes: 308, 288 and 63 genes were upregulated (log2FC > 1); 292, 260 and 45 genes were downregulated (log2FC < ?1) in response to E2 (10 nM), ZEA (10 nM) and BPA (100 nM), respectively. Furthermore, the expression of 13, 11 and 10 miRNAs changed significantly (log2FC > 1, or log2FC < ?1) after exposure to E2, ZEA and BPA, respectively. Functional enrichment analysis of the significantly differentially expressed genes and miRNAs revealed several pathways related to the regulation of cell proliferation and migration. The effect of E2 and ZEA was highly comparable: 407 genes were coregulated by these molecules. We could identify 83 genes that were regulated by all three treatments that might have a significant role in the estrogen response of ovarian cells. Furthermore, the downregulation of several miRNAs (miR-501- 5p, let-7a-2-3p, miR-26a-2-3p, miR-197-5p and miR-582-3p) was confirmed by qPCR, which might support the proliferative effect of estrogens in ovarian cells.
Tárgyszavak:Orvostudományok Elméleti orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
xenoösztrogén
zearalenon
mikotoxin
biszfenol A
petefészekrák
transzkriptomika
mikroRNS
RNS szekvenálás
Megjelenés:Toxins. - 15 : 2 (2023), p. 1-22. -
További szerzők:Beke-Varga Alexandra Edit (1994-) (molekuláris biológus) Penyige András (1954-) (molekuláris genetikus) Hádáné Birkó Zsuzsanna (1971-) (molekuláris genetikus) Balogh István (1972-) (molekuláris biológus, genetikus) Nagy Bálint (1956-) (molekuláris genetikus) Szilágyi Melinda (1984-) (biológus)
Pályázati támogatás:FK138021
OTKA
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

8.

001-es BibID:BIBFORM091613
035-os BibID:(WoS)000632094300001 (Scopus)85101520969
Első szerző:Márton Éva (biológus)
Cím:Comparative Analysis of Cell-Free miR-205-5p, let-7f-5p, and miR-483-5p Expression in Ovarian Cell Cultures and Plasma Samples of Patients with Ovarian Cancer / Éva Márton, Alexandra Varga, Beáta Soltész, András Penyige, János Lukács, Róbert Póka, Bálint Nagy, Melinda Szilágyi
Dátum:2021
Megjegyzések:The term liquid biopsy reveals a non-invasive diagnostic method that might be based on the quantification of cell-free microRNAs in body fluids. However, the identification of candidates for liquid biopsy is challenging. Our aim was to compare the cell-free expression of miR-483-5p, miR-205-5p, and let-7f-5p in ovarian cell cultures and plasma samples of patients with ovarian cancer. Both the intracellular and cell-free expression of miR-205-5p and let-7f-5p proved to be higher in the Estrogen Receptor ? (ER?) expressing PEO1 cell-line than in the estrogen non-sensitive A2780. Moreover, the expression of let-7f-5p was up-regulated in response to estradiol exposure that was diminished after the addition of an ER? selective antagonist. MiR-483-5p had lower intracellular and cell-free expression in PEO1. All these miRNAs had detectable expression level in plasma samples, among which miR-205-5p proved to be overexpressed in the plasma samples of patients with ovarian tumors compared to healthy controls and possessed an acceptable diagnostic potential with ROC-AUC 0.683 (95% CI 0.57?0.795). Functional annotation clustering of the target genes of miR-205-5p revealed several clusters involved in cancer development. We suggest that miR-205-5p might be a promising biomarker candidate in ovarian cancer that should be further analyzed in larger sample size.
Tárgyszavak:Orvostudományok Elméleti orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
microRNA
ovarian cancer
liquid biopsy
Megjelenés:Applied Sciences-Basel. - 11 : 4 (2021), p. 1-10. -
További szerzők:Beke-Varga Alexandra Edit (1994-) (molekuláris biológus) Soltész Beáta (1987-) (molekuláris biológus) Penyige András (1954-) (molekuláris genetikus) Lukács János (1975-) (szülész-nőgyógyász, genetikus) Póka Róbert (1960-) (szülész-nőgyógyász, klinikai onkológus) Nagy Bálint (1956-) (molekuláris genetikus) Szilágyi Melinda (1984-) (biológus)
Pályázati támogatás:ÚNKP-20-3
Egyéb
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

9.

001-es BibID:BIBFORM090169
035-os BibID:(cikkazonosító)9725 (scopus)85098209070 (wos)000603503300001
Első szerző:Márton Éva (biológus)
Cím:The Cell-Free Expression of MiR200 Family Members Correlates with Estrogen Sensitivity in Human Epithelial Ovarian Cells / Éva Márton, Alexandra Varga, Lajos Széles, Lóránd Göczi, András Penyige, Bálint Nagy, Melinda Szilágyi
Dátum:2020
ISSN:1661-6596 1422-0067
Megjegyzések:Exposure to physiological estrogens or xenoestrogens (e.g., zearalenone or bisphenol A) increases the risk for cancer. However, little information is available on their significance in ovarian cancer. We present a comprehensive study on the effect of estradiol, zearalenone and bisphenol A on the phenotype, mRNA, intracellular and cell-free miRNA expression of human epithelial ovarian cell lines. Estrogens induced a comparable effect on the rate of cell proliferation and migration as well as on the expression of estrogen-responsive genes (GREB1, CA12, DEPTOR, RBBP8) in the estrogen receptor ? (ER?)-expressing PEO1 cell line, which was not observable in the absence of this receptor (in A2780 cells). The basal intracellular and cell-free expression of miR200s and miR203a was higher in PEO1, which was accompanied with low ZEB1 and high E-cadherin expression. These miRNAs showed a rapid but intermittent upregulation in response to estrogens that was diminished by an ER?-specific antagonist. The role of ER? in the regulation of the MIR200B-MIR200A-MIR429 locus was further supported by publicly available ChIP-seq data. MiRNA expression of cell lysates correlated well with cell-free miRNA expression. We conclude that cell-free miR200s might be promising biomarkers to assess estrogen sensitivity of ovarian cells.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
ovarian cancer
estrogen
zeralenone
bisphenol
estrogen receptor
cell-free miRNA
miR200
miR203a
EMT
Megjelenés:International Journal of Molecular Sciences. - 21 : 24 (2020), p. 1-19. -
További szerzők:Beke-Varga Alexandra Edit (1994-) (molekuláris biológus) Széles Lajos (1971-) (molekuláris biológus) Göczi Loránd (informatikus) Penyige András (1954-) (molekuláris genetikus) Nagy Bálint (1956-) (molekuláris genetikus) Szilágyi Melinda (1984-) (biológus)
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

10.

001-es BibID:BIBFORM078164
035-os BibID:(PMID)30953675 (WoS)000464978100009 (Scopus)85063866299
Első szerző:Márton Éva (biológus)
Cím:Circulating epithelial-mesenchymal transition-associated miRNAs are promising biomarkers in ovarian cancer / Éva Márton, János Lukács, András Penyige, Eszter Janka, Lídia Hegedüs, Beáta Soltész, Gábor Méhes, Róbert Póka, Bálint Nagy, Melinda Szilágyi
Dátum:2019
ISSN:0168-1656
Megjegyzések:Ovarian cancer is the fifth most common cause of cancer death among women that is mostly due to the difficulty of early diagnosis. Circulating miRNAs proved to be reliable biomarkers in various cancers. We screened 9 miRNAs, which are involved in epithelial-mesenchymal transition, in the plasma samples of patients with malignant (n=28) or non-malignant (n=12) ovarian tumors and disease-free healthy volunteers (n=60) by qRT-PCR. The expression levels of miR200a, miR200b, miR200c, miR141, miR429, miR203a, miR34b (p<0.001) and miR34a (p<0.01) were significantly higher in the malignant samples than in healthy controls. MiR203a, miR141 (p<0.01), miR200a and miR429 (p<0.05) levels were also higher in malignant compared to non-malignant samples. ROC-AUC was the highest in the case of miR200c: 0.861 (95%CI=0.776-0.947). Spearman's rank correlation analysis revealed positive correlation between the plasma levels of the studied miRNAs that was the highest between miR200b and miR200c (rs = 0.774; p<0.001). Target analysis also suggested tight interaction between these miRNAs in the regulation of cancer development. The agreement of diagnostic tests based on miRNA levels and the standard CA125 or HE4 was weak according to Cohen's kappa values. We conclude that miR200 family members, miR34b and miR203a might be promising complementary biomarkers in ovarian cancer.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
petefészekrák
miRNS
miR200
miR34
miR203
CA125
HE4
Megjelenés:Journal of Biotechnology. - 297 (2019), p. 58-65. -
További szerzők:Lukács János (1975-) (szülész-nőgyógyász, genetikus) Penyige András (1954-) (molekuláris genetikus) Janka Eszter Anna (1989-) (bőrgyógyász, népegészségügyi szakember) Hegedüs Lídia Soltész Beáta (1987-) (molekuláris biológus) Méhes Gábor (1966-) (patológus) Póka Róbert (1960-) (szülész-nőgyógyász, klinikai onkológus) Nagy Bálint (1956-) (molekuláris genetikus) Szilágyi Melinda (1984-) (biológus)
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

11.

001-es BibID:BIBFORM080828
035-os BibID:(cikkazonosító)4533 (scopus)85072531584 (wos)000489100500212
Első szerző:Penyige András (molekuláris genetikus)
Cím:Circulating miRNA Profiling in Plasma Samples of Ovarian Cancer Patients / András Penyige, Éva Márton, Beáta Soltész, Melinda Szilágyi-Bónizs, Róbert Póka, János Lukács, Lajos Széles, Bálint Nagy
Dátum:2019
ISSN:1661-6596 1422-0067
Megjegyzések:Ovarian cancer is one of the most common cancer types in women characterized by a high mortality rate due to lack of early diagnosis. Circulating miRNAs besides being important regulators of cancer development could be potential biomarkers to aid diagnosis. We performed the circulating miRNA expression analysis in plasma samples obtained from ovarian cancer patients stratified into FIGO I, FIGO III, and FIGO IV stages and from healthy females using the NanoString quantitative assay. Forty-five miRNAs were di erentially expressed, out of these 17 miRNAs showed significantly di erent expression between controls and patients, 28 were expressed only in patients, among them 19 were expressed only in FIGO I patients. Di erentially expressed miRNAs were ranked by the network-based analysis to assess their importance. Target genes of the di erentially expressed miRNAs were identified then functional annotation of the target genes by the GO and KEGG-based enrichment analysis was carried out. A general and an ovary-specific protein?protein interaction network was constructed from target genes. Results of our network and the functional enrichment analysis suggest that besides HSP90AA1, MYC, SP1, BRCA1, RB1, CFTR, STAT3, E2F1, ERBB2, EZH2, and MET genes, additional genes which are enriched in cell cycle regulation, FOXO, TP53, PI-3AKT, AMPK, TGF , ERBB signaling pathways and in the regulation of gene expression, proliferation, cellular response to hypoxia, and negative regulation of the apoptotic process, the GO terms have central importance in ovarian cancer development. The aberrantly expressed miRNAs might be considered as potential biomarkers for the diagnosis of ovarian cancer after validation of these results in a larger cohort of ovarian cancer patients.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
ovarian cancer
circulating miRNA
blood plasma
NanoString
network analysis
bimarker
Megjelenés:International Journal Of Molecular Sciences. - 20 : 18 (2019), p. E4533. -
További szerzők:Márton Éva (1992-) (biológus) Soltész Beáta (1987-) (molekuláris biológus) Szilágyi Melinda (1984-) (biológus) Póka Róbert (1960-) (szülész-nőgyógyász, klinikai onkológus) Lukács János (1975-) (szülész-nőgyógyász, genetikus) Széles Lajos (1971-) (molekuláris biológus) Nagy Bálint (1956-) (molekuláris genetikus)
Internet cím:DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

12.

001-es BibID:BIBFORM078519
035-os BibID:(PMID)30959137 (WoS)000466942100004 (Scopus)85064114120
Első szerző:Soltész Beáta (molekuláris biológus)
Cím:Expression of CD24 in plasma, exosome and ovarian tissue samples of serous ovarian cancer patients / Beáta Soltész, János Lukács, Edina Szilágyi, Éva Márton, Melinda Szilágyi-Bónizs, András Penyige, Róbert Póka, Bálint Nagy
Dátum:2019
ISSN:0168-1656
Megjegyzések:CD24 is a small molecular weight cell-surface protein and an independent marker for poor prognosis in the different type of cancers. We aimed to determine the expression of CD24 in plasma, exosomes and ovarian tissue samples of serous ovarian cancer patients. We collected tissue and blood samples from 21 cases of serous ovarian cancer and eight healthy controls. We used silica adsorption method for isolation of RNA. The cDNA was synthesized using quantitative real-time PCR. We used beta-globin as a housekeeping gene for the normalization of the data. Protein-protein and miRNA networking were analyzed. There was a significant difference in the expression of CD24 in ovarian tissue between controls and patients (0.16?±?0.32 vs. 44.97?±?68.06; p?<?0.01), while CD24 did not show expression in each plasma and exosome samples. There was a correlation in the expression of CD24 and FIGO grading between controls and patients. CD24 expression was detected in exosomes in 38.1% of patients, mainly with FIGO III, and in their plasma in 9.5% of cases. Our network analysis shows LYN, SELP, FGR, and NPM1 proteins are interacting with CD24. Our study demonstrates higher expression of CD24 in ovarian cancer patients' tissue samples, and there is an association with FIGO classification. However, CD24 showed expression only in some cell-free plasma and exosome samples.
Tárgyszavak:Orvostudományok Elméleti orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
CD24
Cell-free nucleic acids
Exosomes
Ovarian cancer
Plasma
Megjelenés:Journal of Biotechnology. - 298 (2019), p. 16-20. -
További szerzők:Lukács János (1975-) (szülész-nőgyógyász, genetikus) Szilágyi Edina (1993-) (laboratóriumi analitikus) Márton Éva (1992-) (biológus) Szilágyi Melinda (1984-) (biológus) Penyige András (1954-) (molekuláris genetikus) Póka Róbert (1960-) (szülész-nőgyógyász, klinikai onkológus) Nagy Bálint (1956-) (molekuláris genetikus)
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Rekordok letöltése1 2 
Corvina könyvtári katalógus v8.2.27 © 2023 Monguz kft. Minden jog fenntartva.